Armata Pharmaceuticals, Inc. (ARMP)
NYSEAMERICAN: ARMP · Real-Time Price · USD
3.140
-0.060 (-1.88%)
Oct 7, 2025, 12:58 PM EDT - Market open
Armata Pharmaceuticals Revenue
Armata Pharmaceuticals had revenue of $2.17M in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to $6.87M, up 84.67% year-over-year. In the year 2024, Armata Pharmaceuticals had annual revenue of $5.17M with 14.24% growth.
Revenue (ttm)
$6.87M
Revenue Growth
+84.67%
P/S Ratio
16.86
Revenue / Employee
$114,467
Employees
60
Market Cap
113.76M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 5.17M | 645.00K | 14.24% |
| Dec 31, 2023 | 4.53M | -979.00K | -17.77% |
| Dec 31, 2022 | 5.51M | 1.03M | 23.11% |
| Dec 31, 2021 | 4.47M | 3.65M | 443.62% |
| Dec 31, 2020 | 823.00K | - | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ARMP News
- 4 weeks ago - Armata Pharmaceuticals Announces Structural Biology Publication in the Journal of Molecular Biology - PRNewsWire
- 4 weeks ago - Armata Pharmaceuticals to Participate in the H.C. Wainwright 27th Annual Global Investment Conference - PRNewsWire
- 7 weeks ago - Armata Pharmaceuticals Announces Second Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces Positive Topline Data from the Phase 1b/2a diSArm Study of Intravenously Administered AP-SA02 in Complicated Staphylococcus aureus Bacteremia - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Announces First Quarter 2025 Results and Provides Corporate Update - PRNewsWire
- 5 months ago - Armata Pharmaceuticals Receives $4.65 Million of Additional Non-Dilutive Award Funding from the U.S. Department of Defense to Support Ongoing diSArm Clinical Trial of AP-SA02 - PRNewsWire
- 7 months ago - Armata Pharmaceuticals Announces Fourth Quarter and Full-Year 2024 Results and Provides Corporate Update - PRNewsWire
- 7 months ago - Armata Pharmaceuticals Announces $10 Million Secured Credit Agreement with Innoviva - PRNewsWire